CGEM (Cullinan Therapeutics) Dividend Payout Ratio : 0.00 (As of Dec. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cullinan Therapeutics Dividend Payout Ratio?

The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Cullinan Therapeutics's Dividend Payout Ratio for the months ended in Dec. 2024 was 0.00.

The historical rank and industry rank for Cullinan Therapeutics's Dividend Payout Ratio or its related term are showing as below:

CGEM's Dividend Payout Ratio is not ranked ^*
in the Biotechnology industry.
Industry Median: 0.45
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2025-03-17), the Dividend Yield % of Cullinan Therapeutics is 0.00%.

Cullinan Therapeutics's Dividends per Share for the months ended in Dec. 2024 was $0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.

Cullinan Therapeutics Dividend Payout Ratio Historical Data

The historical data trend for Cullinan Therapeutics's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cullinan Therapeutics Dividend Payout Ratio Chart

Cullinan Therapeutics Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dividend Payout Ratio

Get a 7-Day Free Trial

Cullinan Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Cullinan Therapeutics's Dividend Payout Ratio

For the Biotechnology subindustry, Cullinan Therapeutics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cullinan Therapeutics's Dividend Payout Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cullinan Therapeutics's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where Cullinan Therapeutics's Dividend Payout Ratio falls into.

Cullinan Therapeutics Dividend Payout Ratio Calculation

Cullinan Therapeutics's Dividend Payout Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2024 )	/	EPS without NRI (A: Dec. 2024 )
	=	0	/	-2.78
	=	N/A

Cullinan Therapeutics's Dividend Payout Ratio for the quarter that ended in Dec. 2024 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2024 )	/	EPS without NRI (Q: Dec. 2024 )
	=	0	/	-0.73
	=	N/A

Cullinan Therapeutics (NAS:CGEM) Dividend Payout Ratio Explanation

In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

Cullinan Therapeutics Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of Cullinan Therapeutics's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Cullinan Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cullinan Therapeutics Inc (NAS:CGEM) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Main Street, Suite 1350, Cambridge, MA, USA, 02142

Website

https://cullinantherapeutics.com

Cullinan Therapeutics Inc is a biopharmaceutical company. It has diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Its understanding of oncology, immunology, and translational medicine, create differentiated ideas, identify the appropriate targets, and select the optimal modality to develop transformative therapeutics across a variety of cancer and autoimmune indications.

Executives

Jennifer Michaelson	officer: See Remarks	C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Nadim Ahmed	director, officer: President and CEO	C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Jacquelyn L Sumer	officer: Chief Legal Officer	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
Jeffrey Alan Jones	officer: Chief Medical Officer	ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Savill Corrine	officer: Acting Chief Business Officer	C/O CULLINAN ONCOLOGY, LLC, ONE MAIN STREET SUITE 520, CAMBRIDGE MA 02142
Jeffrey Trigilio	officer: Chief Financial Officer	C/O CULLINAN MANAGEMENT, INC., ONE MAIN STREET, SUTIE 520, CAMBRIDGE MA 02142
David P. Ryan	director	C/O CULLINAN ONCOLOGY, INC., ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Vision Scs F2	10 percent owner	74 GRAND RUE, LUXEMBURG N4 L-1660
F2 Bioscience I 2017 Ltd	10 percent owner	8, RUE SAINT-LEGER, GENEVA V8 CH 1205
Biotechnology Value Fund L P	other: See Explanation of Responses	44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Anne-marie Martin	director	ONE MAIN STREET, SUITE 520, CAMBRIDGE MA 02142
Biotechnology Value Trading Fund Os Lp	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Bvf Partners Os Ltd.	other: See Explanation of Responses	P.O. BOX 309 UGLAND HOUSE, GRAND CAYMAN E9 KY1-1104
Mark N Lampert	10 percent owner	1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Bvf I Gp Llc	other: See Explanation of Responses	44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104